Drugs / ALN-AAT
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02503683 Comparator | Jul 2015 → Jan 2018 | alpha 1-antitrypsin deficiency | Alnylam Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-AAT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02503683 ↗ |
| Route | Subcutaneous | “by subcutaneous (sc) injection” NCT02503683 ↗ |